176 related articles for article (PubMed ID: 34874603)
1. Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease.
De Kort AM; Kuiperij HB; Kersten I; Versleijen AAM; Schreuder FHBM; Van Nostrand WE; Greenberg SM; Klijn CJM; Claassen JAHR; Verbeek MM
Alzheimers Dement; 2022 Oct; 18(10):1788-1796. PubMed ID: 34874603
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy.
Banerjee G; Ambler G; Keshavan A; Paterson RW; Foiani MS; Toombs J; Heslegrave A; Dickson JC; Fraioli F; Groves AM; Lunn MP; Fox NC; Zetterberg H; Schott JM; Werring DJ
J Alzheimers Dis; 2020; 74(4):1189-1201. PubMed ID: 32176643
[TBL] [Abstract][Full Text] [Related]
3. The relation of a cerebrospinal fluid profile associated with Alzheimer's disease with cognitive function and neuropsychiatric symptoms in sporadic cerebral amyloid angiopathy.
De Kort AM; Kaushik K; Kuiperij HB; Jäkel L; Li H; Tuladhar AM; Terwindt GM; Wermer MJH; Claassen JAHR; Klijn CJM; Verbeek MM; Kessels RPC; Schreuder FHBM
Alzheimers Res Ther; 2024 May; 16(1):99. PubMed ID: 38704569
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy.
De Kort AM; Kuiperij HB; Alcolea D; Kersten I; Versleijen AAM; Greenberg SM; Stoops E; Schreuder FHBM; Klijn CJM; Lleó A; Claassen JAHR; Verbeek MM
Alzheimers Res Ther; 2021 Sep; 13(1):160. PubMed ID: 34560885
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.
Renard D; Wacongne A; Ayrignac X; Charif M; Fourcade G; Azakri S; Le Floch A; Bouly S; Marelli C; Arquizan C; Hirtz C; Gabelle A; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016; 50(3):759-764. PubMed ID: 26757185
[TBL] [Abstract][Full Text] [Related]
6. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis.
Charidimou A; Friedrich JO; Greenberg SM; Viswanathan A
Neurology; 2018 Feb; 90(9):e754-e762. PubMed ID: 29386280
[TBL] [Abstract][Full Text] [Related]
7. Interest of CSF biomarker analysis in possible cerebral amyloid angiopathy cases defined by the modified Boston criteria.
Renard D; Castelnovo G; Wacongne A; Le Floch A; Thouvenot E; Mas J; Gabelle A; Labauge P; Lehmann S
J Neurol; 2012 Nov; 259(11):2429-33. PubMed ID: 22576334
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF
Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cerebrospinal fluid profiles in Alzheimer's disease with multiple cerebral microbleeds and cerebral amyloid angiopathy-related inflammation.
Kimura A; Takemura M; Saito K; Yoshikura N; Hayashi Y; Harada N; Nishida H; Nakajima H; Inuzuka T
J Neurol; 2017 Feb; 264(2):373-381. PubMed ID: 28000005
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ42, and Aβ40 in Probable Cerebral Amyloid Angiopathy.
Grangeon L; Paquet C; Guey S; Zarea A; Martinaud O; Rotharmel M; Maltête D; Quillard-Muraine M; Nicolas G; Charbonnier C; Chabriat H; Wallon D
J Alzheimers Dis; 2022; 87(2):791-802. PubMed ID: 35367960
[TBL] [Abstract][Full Text] [Related]
11. Aβ38 and Aβ43 do not differentiate between Alzheimer's disease and cerebral amyloid angiopathy.
Dargvainiene J; Jensen-Kondering U; Bender B; Berg D; Brüggemann N; Flüh C; Markewitz R; Neumann A; Röben B; Röcken C; Royl G; Schulte C; Wandinger KP; Weiler C; Margraf NG; Kuhlenbäumer G
Ann Clin Transl Neurol; 2024 Mar; 11(3):806-811. PubMed ID: 38186185
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Isolated Supratentorial Cortical Superficial Siderosis.
Renard D; Gabelle A; Hirtz C; Demattei C; Thouvenot E; Lehmann S
J Alzheimers Dis; 2016 Oct; 54(4):1291-1295. PubMed ID: 27567848
[TBL] [Abstract][Full Text] [Related]
13. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
[TBL] [Abstract][Full Text] [Related]
14. Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina.
Shi H; Koronyo Y; Rentsendorj A; Regis GC; Sheyn J; Fuchs DT; Kramerov AA; Ljubimov AV; Dumitrascu OM; Rodriguez AR; Barron E; Hinton DR; Black KL; Miller CA; Mirzaei N; Koronyo-Hamaoui M
Acta Neuropathol; 2020 May; 139(5):813-836. PubMed ID: 32043162
[TBL] [Abstract][Full Text] [Related]
15. Cerebral Amyloid Angiopathy-Related Microbleeds and Cerebrospinal Fluid Biomarkers in Alzheimer's Disease.
Noguchi-Shinohara M; Komatsu J; Samuraki M; Matsunari I; Ikeda T; Sakai K; Hamaguchi T; Ono K; Nakamura H; Yamada M
J Alzheimers Dis; 2017; 55(3):905-913. PubMed ID: 27802236
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal Fluid Panel of Synaptic Proteins in Cerebral Amyloid Angiopathy and Alzheimer's Disease.
van den Berg E; Nilsson J; Kersten I; Brinkmalm G; de Kort AM; Klijn CJM; Schreuder FHBM; Jäkel L; Gobom J; Portelius E; Zetterberg H; Brinkmalm A; Blennow K; Kuiperij HB; Verbeek MM
J Alzheimers Dis; 2023; 92(2):467-475. PubMed ID: 36776062
[TBL] [Abstract][Full Text] [Related]
17. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
18. Biomarkers in subtypes of mild cognitive impairment and subjective cognitive decline.
Eliassen CF; Reinvang I; Selnes P; Grambaite R; Fladby T; Hessen E
Brain Behav; 2017 Sep; 7(9):e00776. PubMed ID: 28948074
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy of cerebrospinal fluid identifies neuronal pentraxin receptor (NPTXR) as a biomarker of progression of Alzheimer's disease.
Lim B; Tsolaki M; Soosaipillai A; Brown M; Zilakaki M; Tagaraki F; Fotiou D; Koutsouraki E; Grosi E; Prassas I; Diamandis EP
Clin Chem Lab Med; 2019 Nov; 57(12):1875-1881. PubMed ID: 31415236
[TBL] [Abstract][Full Text] [Related]
20. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
